Literature DB >> 15052501

Secondary surgery in germ cell tumors--when and how extensively should it be performed?

Richard S Foster1, Stephen Beck, Richard Bihrle.   

Abstract

Postchemotherapy RPLND has been used for several decades. Two current issues relating to this surgery are discussed in this article. The selection for surgery and the extent of surgery to be performed continue to evolve.

Entities:  

Mesh：

Year:  2004        PMID： 15052501     DOI： 10.1007/s00345-004-0402-3

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  16 in total

1.  RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.

Authors:  L Weissbach; R Bussar-Maatz; H Flechtner; U Pichlmeier; M Hartmann; L Keller
Journal:  Eur Urol       Date:  2000-05       Impact factor: 20.096

2.  Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors.

Authors:  N L Geller; G J Bosl; E Y Chan
Journal:  Cancer       Date:  1989-02-01       Impact factor: 6.860

3.  Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors.

Authors:  D J Debono; D K Heilman; L H Einhorn; J P Donohue
Journal:  J Clin Oncol       Date:  1997-04       Impact factor: 44.544

4.  Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma.

Authors:  G R Wahle; R S Foster; R Bihrle; R G Rowland; R M Bennett; J P Donohue
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

5.  Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.

Authors:  M De Santis; C Bokemeyer; A Becherer; F Stoiber; K Oechsle; K Kletter; B M Dohmen; C Dittrich; J Pont
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

6.  Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.

Authors:  C L Coogan; R S Foster; R G Rowland; R Bihrle; E R Smith; L H Einhorn; B J Roth; J P Donohue
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

7.  Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.

Authors:  D P Wood; H W Herr; G Heller; V Vlamis; P C Sogani; R J Motzer; W R Fair; G J Bosl
Journal:  J Urol       Date:  1992-12       Impact factor: 7.450

8.  Complications of post-chemotherapy retroperitoneal lymph node dissection.

Authors:  J Baniel; R S Foster; R G Rowland; R Bihrle; J P Donohue
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

9.  Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

Authors:  S D Fosså; H Qvist; A E Stenwig; H H Lien; S Ous; K E Giercksky
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

10.  Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.

Authors:  P J Loehrer; D Johnson; P Elson; L H Einhorn; D Trump
Journal:  J Clin Oncol       Date:  1995-02       Impact factor: 44.544
View more
  1 in total

1.  Therapeutic supine robotic retroperitoneal lymph node dissection for post-chemotherapy residual masses in testicular cancer: technique and outcome analysis of initial experience.

Authors:  Ashwin Sunil Tamhankar; Saurabh Ramesh Patil; Surya Prakash Ojha; Puneet Ahluwalia; Gagan Gautam
Journal:  J Robot Surg       Date:  2019-01-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.